

HPMS E-Mail

Date: December 8, 2021

Subject: Correction: “Permissible Flexibilities Related to Oral Antiviral Drugs for Treatment of COVID-19 that May Receive U.S. FDA Emergency Use Authorization and are Procured by the U.S. Government” 11/23/21

The November 23, 2021 memo, “Permissible Flexibilities Related to Oral Antiviral Drugs for Treatment of COVID-19 that May Receive U.S. FDA Emergency Use Authorization and are Procured by the U.S. Government,” incorrectly directed Part D sponsors to consult NCPDP Emergency Preparedness Guidance for “Billing for Reimbursement of a Free Product (No Associated Cost) with No Administration Fee” to prepare for paying pharmacy claims for dispensing fees for U.S. Government-procured oral antivirals for COVID-19. The correct section of the NCPDP Emergency Preparedness Guidance applicable to this scenario is “Billing of a Self-Administered Free Product During an Emergency.”